Contents

MTEC at a Glance 3
From The Chair 4
2022 Performance Highlights 5
Funding & Membership 6-7
Strategic Partnerships 8-9
Military Infectious Diseases 10-11
Combat Casualty Care 12-13
Military Operational Medicine 14-15
Medical Simulation & Information Sciences 16-17
Clinical & Rehabilitative Medicine 18-19
MTEC Connecting Members 20
Commercialization Grants 21
2022 Member Awards & Recognition 22-23
Testimonials 24
Member Impact in Ukraine 25
Timeline 26-27
2023 Strategic Goals 28-29
Tribute to CAPT (ret) Russ Keller 30

WHO WE ARE

The Medical Technology Enterprise Consortium (MTEC) is a non-profit biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command (USAMRDC) located at Fort Detrick, Maryland. MTEC aims to propel innovative technologies forward within the medical space to meet both military and civilian needs.

HOW WE WORK

Defense and private sponsors fund RESEARCH & DEVELOPMENT

600+ member organizations collaborate to develop MEDICAL TECHNOLOGY SOLUTIONS

THE IMPACT

Military and Civilian Markets

2345ln m

CCTCMte8E

Coto

MTEC at a Glance 3
From The Chair 4
2022 Performance Highlights 5
Funding & Membership 6-7
Strategic Partnerships 8-9
Military Infectious Diseases 10-11
Combat Casualty Care 12-13
Military Operational Medicine 14-15
Medical Simulation & Information Sciences 16-17
Clinical & Rehabilitative Medicine 18-19
MTEC Connecting Members 20
Commercialization Grants 21
2022 Member Awards & Recognition 22-23
Testimonials 24
Member Impact in Ukraine 25
Timeline 26-27
2023 Strategic Goals 28-29
Tribute to CAPT (ret) Russ Keller 30

WHO WE ARE

The Medical Technology Enterprise Consortium (MTEC) is a non-profit biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command (USAMRDC) located at Fort Detrick, Maryland. MTEC aims to propel innovative technologies forward within the medical space to meet both military and civilian needs.

HOW WE WORK

Defense and private sponsors fund RESEARCH & DEVELOPMENT

600+ member organizations collaborate to develop MEDICAL TECHNOLOGY SOLUTIONS

THE IMPACT

Military and Civilian Markets

2345ln m

CCTCMte8E

Coto

MTEC at a Glance 3
From The Chair 4
2022 Performance Highlights 5
Funding & Membership 6-7
Strategic Partnerships 8-9
Military Infectious Diseases 10-11
Combat Casualty Care 12-13
Military Operational Medicine 14-15
Medical Simulation & Information Sciences 16-17
Clinical & Rehabilitative Medicine 18-19
MTEC Connecting Members 20
Commercialization Grants 21
2022 Member Awards & Recognition 22-23
Testimonials 24
Member Impact in Ukraine 25
Timeline 26-27
2023 Strategic Goals 28-29
Tribute to CAPT (ret) Russ Keller 30

WHO WE ARE

The Medical Technology Enterprise Consortium (MTEC) is a non-profit biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command (USAMRDC) located at Fort Detrick, Maryland. MTEC aims to propel innovative technologies forward within the medical space to meet both military and civilian needs.

HOW WE WORK

Defense and private sponsors fund RESEARCH & DEVELOPMENT

600+ member organizations collaborate to develop MEDICAL TECHNOLOGY SOLUTIONS

THE IMPACT

Military and Civilian Markets
From The Chair

In my inaugural year as Chair of the MTEC Board, I am both honored to serve and impressed by my fellow MTEC Board members, leadership, and community. 2022 proved to be yet another growth year for the organization. We achieved a membership milestone by exceeding 600 members. We have distributed over $700M in funding since inception. We have deepened relations with all member stakeholder sets – sponsors, collaborators, industry, academic institutions, foundations and investors. We are actively building out our investor network in order to address member funding needs. We are collaborating with federal health agencies and enhancing relations with the Defense Health Agency as the transition to its leadership occurs in the military research and development investments and programs.

2022 presented new opportunities for MTEC leadership, including sponsorship of military medical fellowships in collaboration with the American Psychiatric Association Foundation, the Milken Institute Health Summit, the American Brain Coalition, and the Orthopedic Research and Education Foundation (OREF), to name a few. These efforts have been years in the making. MTEC’s dedication to serving you, sponsors, members, and stakeholders, is the foundation on which these opportunities are built.

Special thanks to our professional staff who continue to be high performing, especially with communications and outreach to all of you. We hosted a record number of webinars, events, scouting and pitch competitions. Our team is building commercialization services, subject matter expert networks through our M-Corps Partners, and a growing portfolio of projects selected for funding by our sponsors.

We look forward to growing and learning with you in 2023 to keep our military medical enterprise healthier and stronger than ever.

Ellen Embrey
MTEC Board Chair, 2022-Present

2022 Performance Highlights

$154.4M IN NEW FUNDING
awarded across 62 new projects

9 FUNDING OPPORTUNITIES
covering 26 topic areas

51 CLOSED-OUT PROJECTS
resulting in 7 commercial products

169 ACTIVE PROPOSALS IN THE BASKET

4-5 AVERAGE TECHNOLOGY READINESS LEVEL

PUBLISHED CAMPAIGNS
30+

HOSTED
27 WEBINARS
REACHING A TOTAL OF 1337 MEMBERS

40+
EVENTS ATTENDED BY MTEC TEAM

EVALUATED
2K+
COMPANIES FOR MILITARY RELEVANCE

20K+
HUMAN SUBJECTS ENROLLED IN STUDIES

OF PROJECTS HAVE SECURED FUNDING FOLLOWING MTEC AWARD
47%

OF PROJECTS ARE DOING HUMAN SUBJECT TESTING
30%

OF PROJECTS INTERACTED WITH U.S. FDA
25%

BRIDGE FUNDING
provided through
- PROTOTYPE ACCELERATION AWARDS
- COMMERCIALIZATION GRANTS

"2022 proved to be a year of growth and funding diversification"
Funding Distribution

$781M MILITARY SPONSOR FUNDING
New Awards, Incremental Funding, and Follow On

Since inception

Funding Distribution

$884M including $103M Cost Share

Projects Since Inception
232 PROJECTS

Membership at 2022 Calendar Year’s End

Membership Growth Since Inception

SMALL BUSINESSES
ACADEMIA
LARGE INDUSTRY
MULTI-MEMBERS
NON-PROFITS

415
92
46
9
40

4 15 31 57 117 170 232
Strategic Partnerships

MTEC engaged in several partnerships to increase research opportunities, capabilities, and visibility for medical issues of importance to both the military and civilians.

MedTech Innovator facilitated introductions for 17 companies to USAMRDC through Pitch Days.

OREF partnered with Military Operational Medicine Research Program (MOMRP) to search for solutions to musculoskeletal injuries.

ARCH Venture Partners supported USAMRDC with technology deep dives.

Joining New Coalitions of Leaders

MTEC is now a member of the American Brain Coalition, a network of the country’s leading professional neurological, psychological, and psychiatric associations and nonprofits.

MTEC is a member of the American Brain Coalition, a network of the country’s leading professional neurological, psychological, and psychiatric associations and nonprofits.

Fostering Research in Military Mental Health

MTEC’s sponsorship of the American Psychiatric Association’s Research Colloquium for Junior Psychiatrist Investigators added a military mental health track to its curriculum, focusing on Post-Traumatic Stress Disorder, Suicide, and Traumatic Brain Injury (TBI).

Connecting with Changemakers

MTEC participated in the Milken Institute’s Future of Health Summit, with Dr. Terry Rauch joining an esteemed group of panelists, to discuss pandemic preparedness to an audience of over 750 business leaders, policymakers, philanthropists, academics, investors, researchers, and scientists.

Defense Threat Reduction Agency (DTRA) sponsored their first Request for Proposals.
OBJECTIVE
Prevent, predict, and treat infectious disease threats to eliminate their impacts on operational readiness and performance.

AREAS OF INTEREST:
- Pathogen agnostic countermeasures to prevent and treat sepsis caused by wound infections
- Prevention and treatment of biofilm formation
- Prophylactic for endemic diarrheal diseases
- Broad spectrum antivirals to prevent and treat endemic and emerging infectious diseases
- Diagnostics for invasive fungal infections
- Prophylactic to prevent infection in battlefield wounds
- Wound care technologies to treat combat wound infections

2022 NEW FUNDING: $11,766,590
2022 FUNDING INCREASES: $13,310,050
NEW PROJECT SPONSORS: CCRP, DTRA, MIDRP, NMRC
NEW PROJECT AWARDEES:

Project Highlights

Armata Pharmaceuticals
Bacteriophage Therapeutics for Infection Control
Armata is developing a novel bacteriophage therapeutic, AP-SA02, to treat patients with Staphylococcus aureus bacteremia. Armata initiated a Phase 1b/2a study of the safety, tolerability, and efficacy of intravenous AP-SA02.

VxBiosciences
Therapeutic Interfering Particles for Viral Disease Treatment
VxBiosciences is advancing therapeutic interfering particles (TIPs) as a new class of single-administration antiviral treatments. TIPs have been shown to inhibit the SARS-CoV-2 virus, reduce viral loads, and suppress inflammation and severe disease in a hamster model.

Inhalon Biopharma
Immunotherapies for Respiratory Infection
Inhalon is developing immunotherapies with an inhaled muco-trapping antibody platform to prevent and treat acute respiratory infections. Inhalon completed a Phase 1 clinical study which demonstrated good tolerability and achieved concentrations in the respiratory tract above its inhibitory concentration.

Funding: $16M
Funding: $11M
Funding: $7M
**OBJECTIVE**

Reduce mortality and morbidity associated with combat trauma from the battlefield to hospital.

**AREAS OF INTEREST:**
- Prolonged field care
- Therapeutics for ischemia reperfusion injury
- Wound care treatments for use at point of injury
- Solutions for non-compressible (i.e., truncal) hemorrhage
- Burn assessment, care and training tools
- Surgical support for damage control procedures for use in far forward and austere settings
- Technologies or therapeutics for management of lung and kidney organ injury/failure
- Warfighter brain health and injury

---

**ULURU**

**Far-Forward Wound Care**

ULURU is developing a cost-effective wound care technology, Altrazeal, that can be applied at the point-of-injury to enable early wound healing. ULURU is currently evaluating efficacy of Altrazeal in patients with diabetic foot ulcers.

---

**Astrocyte Pharmaceuticals**

**Pharmaceutical for TBI Management**

Astrocyte is developing a cerebroprotective therapeutic, AST-004, as a far forward treatment for traumatic brain injury. They have completed a Phase 1 clinical trial enabling advancement toward a Phase 2 trial.

---

**Indiana University**

**Electroceutical Wound Management**

The Roy Lab has co-developed a novel bandage platform called electroceutical dressing technologies, that mitigates wound biofilm and combats antibiotic resistant infections by making bacteria susceptible to available antibiotics at the point-of-injury. This technology can be used to significantly reduce or eliminate infection, improved wound closure, and enhance proper skin function during the healing process.
MILITARY OPERATIONAL MEDICINE

OBJECTIVE
Maximize health, readiness, and performance by countering, preventing, and treating injuries.

AREAS OF INTEREST:
- Adjustment disorders treatments
- Prevention, treatment of decompression sickness
- Post-traumatic Stress Disorder
- Management of circadian disruption
- Musculoskeletal injury prevention, treatment, and rehabilitation
- Warfighter performance optimization
- Sex-specific training and strategies to promote readiness
- Warfighter and family psychological health and resilience to stressors

2022 NEW FUNDING: $39,196,518
2022 FUNDING INCREASES: $12,616,532

NEW PROJECT SPONSORS: MOMRP, NMRC, USAMMDA, USARIEM
NEW PROJECT Awardees:
- International Fabric Machines

2022 NEW FUNDING:
- University of Maryland
  - Sleep Disorders and Research Center
    - Personalized Sleep Improvement Software
    - The Center has developed software that leverages personalized sleep assessments, remote monitoring, and big data analytics to improve outcomes and reduce costs. The team has completed a large-scale roll-out into joint service military hospitals.

- University of California San Francisco
  - Pathogen Detection via Oura Ring
    - Researchers have found that algorithms using information collected by the commercially available Oura Ring may detect pathogens such as COVID-19 before formal diagnosis.

- NIRSense
  - Wearable Deep Tissue Oxygen Monitoring
    - NIRSense is advancing a ruggedized wearable system to monitor oxygen 10x deeper than pulse oximetry. This system alerts military users to the risks of physiological degradation in the operational environment. The system is preparing for a definitive clinical trial this summer and submission to the FDA this fall.
Medical Simulation & Information Sciences

OBJECTIVE
Optimize front line medical care and interventions through robotics, intelligent systems, and improved education and training.

AREAS OF INTEREST:
- Trainings that optimize practice and effectiveness
- Artificial intelligence to support medical resupply in theater
- Battlefield medical automation
- Autonomous care and AI at the point-of-injury in austere environments
- Remote tele-monitoring
- Health informatics
- Next generation casualty management
- Human-machine integration
- Interoperable haptic platforms to support virtual and augmented education tools
- Interoperable automatic systems

Applied Research Associates
Hemorrhage Risk Assessment
The team has developed AI models for assessing the risk of internal hemorrhage and calculating the probability of shock, which will enable the rapid diagnosis and treatment of trauma symptoms and lead to reduced morbidity and mortality.

Information Visualization and Innovative Research (IVIR)
Joint Emergency Trauma Simulation
The Joint Emergency Trauma Simulation system enables standardized, integrated, state-of-the-art training through an interconnected web of systems designed to serve as joint simulations to track patient movement from the point of injury to a controlled medical area. IVIR has completed their funded scope of work with a demonstration of the final prototype system to the military. Further pilot testing and refinement is pending.

Charles River Analytics
Trauma Assessment Training
The team has developed a mobile system for TCCC training that improves the availability of trauma scenarios in a variety of virtual operational environments necessary for practice and skills maintenance. This award has been completed.

Project Highlights

- **Funding:** $4M
- **Applied Research Associates**
- **Hemorrhage Risk Assessment**

- **Funding:** $5M
- **Information Visualization and Innovative Research (IVIR)**
- **Joint Emergency Trauma Simulation**

- **Funding:** $1M
- **Charles River Analytics**
- **Trauma Assessment Training**

2022 NEW FUNDING: $8,316,825
NEW PROJECT SPONSORS: CCCRP, USAMMDA, USUHS
NEW PROJECT Awardees:
Booz | Allen | Hamilton

2022 FUNDING INCREASES: $16,527,274

Funding:
- $4M
- $5M
- $1M
OBJECTIVE
Improve restorative treatments and rehabilitative care to maximize function for return to duty or civilian life.

AREAS OF INTEREST:
- Craniomaxillofacial regeneration
- Extremity and soft tissue regeneration (bone, muscle, and/or nerve)
- Genitourinary/lower abdomen reconstruction
- Skin regeneration
- Ex-vivo/on-demand blood
- Sensory system (vision, hearing, balance) preservation and restoration
- Cellular therapies for trauma and critical care
- Prevention and treatment of dental pain and infections
- Ex-vivo/on-demand blood
- Sensory system (vision, hearing, balance) preservation and restoration
- Cellular therapies for trauma and critical care
- Prevention and treatment of dental pain and infections
- Ex-vivo/on-demand blood
- Sensory system (vision, hearing, balance) preservation and restoration
- Cellular therapies for trauma and critical care
- Prevention and treatment of dental pain and infections

RegenMed Development Organization (ReMDO)
Universal Media for Cell Production
ReMDO has been developing universal media with the overall goal of producing unifying culture medias, both serum-free and xeno-free, with compatible bio-coatings for the expansion of numerous clinically relevant human primary cells derived from each germ layer.

Scientific & Biomedical Microsystems
Neuronal Interface for Vision Restoration
The team has developed a prototype system with cutting-edge hardware and software platforms for high-density next generation neuronal recording and stimulation. The ultimate goal is to demonstrate visual prosthetics. The project has shown safety and efficacy in non-human primates and been safely used in six human patients thus far.

Southwest Research Institute
3D Printed Bioreactor System
The Institute is working to streamline stem cell manufacturing by using a novel 3D printed bioreactor system. The team has successfully demonstrated a scalable expansion of stem cells and stem cell-derived exosomes. This novel bioreactor platform is promising for manufacturing many cell-derived biologics.

NEW PROJECT SPONSORS: MOMRP, NMRC
NEW PROJECT Awardees:

Project Highlights

Funding: $5M

Funding: $2M

Funding: $3M

2022 NEW FUNDING: $12,358,891
2022 FUNDING INCREASES: $5,301,314
MTEC awarded 13 Commercialization Grants totaling over $580K in non-dilutive funds to small business members. These grants facilitated partnerships with M-Corps partners to address business planning strategies for product development.

Below are 3 awardees and the impact the partnership had on each project’s success:

**Awardee:** Haima Therapeutics  
**M-Corps:** Alira Health  
**Project Goal:** Complete a market access strategy for its SynthoPlate Artificial Platelet platform.  
**Outcome:** Alira provided insight into the clinical and reimbursement strategies that Haima needed for launch.

"Alira provided a report that we were able to share with interested parties to increase excitement and support for our program."

Michael Bruckman, Haima Therapeutics CEO

**Awardee:** Lumen Biotechnology  
**M-Corps:** Latham Biopharmaceutical Group  
**Project Goal:** Complete a commercialization analysis and plan for Traveler’s Diarrhea Therapeutic.  
**Outcome:** The strategy devised invigorated Lumen’s belief in the value of the product and solidified the commercial plan.

"The strategy devised invigorated our belief in the value of the product and solidified the commercial plan."

Brian Finrow, Lumen Co-founder and CEO

**Awardee:** KeriCure Medical  
**M-Corps:** CNTR (Collaboration on National Trauma Research)  
**Project Goal:** Complete a clinical trial protocol and supporting statistical plan.  
**Outcome:** CNTR’s guidance helped get the proposal selected by Joint Warfighter Medical Research Program for a 3 year, $3.2M contract.

"MTEC’s support led to the first clinical trial for KeriCure, a huge win for us!"

Dr. Kerriann Greenhalgh, KeriCure Medical CEO and CSO

"We now have a solid plan, backed by third-party research, to ensure we get this to as many patients as possible."

Brian Finrow, Lumen Co-founder and CEO
2022 MTEC Member Awards & Recognition

**MTEC**

7th Annual Membership Meeting Awards

**TechConnect**

Medical Innovation Challenge

awarded 7 companies (5 MTEC members) totaling $250K

**MEDTECH INNOVATOR**

Military Pitch Competition

awarded 5 companies with MTEC membership

**Prototype Acceleration “Bridge” Awards**

awarded 5 MTEC awards totaling $1M

Sponsor Recognition:

Prototype of the Year:

Impact:

Sensate Medical

SurgiBox

Military Pitch Competition awarded 5 companies with MTEC membership

Prototype Acceleration “Bridge” Awards awarded 5 MTEC awards totaling $1M

MTEC

7th Annual Membership Meeting Awards

TechConnect

Medical Innovation Challenge awarded 7 companies (5 MTEC members) totaling $250K

MEDTECH INNOVATOR

Military Pitch Competition

Prototype Acceleration “Bridge” Awards

Sensate Medical

SurgiBox
“Musculoskeletal injuries exact a tremendous toll on our Service members and OREF is delighted to collaborate with MTEC and MOMRP to offer this incredible opportunity, which will provide significant funding for research focused on accelerating return-to-readiness for Service members affected by musculoskeletal injuries.”
COL James R. Ficke, MD, U.S. Army (ret), Trustee, Orthopaedic Research and Education Foundation, oref.org

MTEC MEMBERS

“MTEC has been the perfect partner – providing critical funding, facilitating key discussions with the DoD USAMRDC, and enabling our potential TBI therapeutic to successfully advance through Phase 1 clinical studies.”
William S. Korinek, PhD, CEO, Astrocyte Pharmaceuticals Inc, astrocytepharma.com

“GE Research is proud to collaborate with MTEC on projects that not only help improve the quality of care for our nation’s military and veterans, but also bring these solutions to the broader healthcare community. It’s an important way we can help drive GE HealthCare’s broader commitment of enabling a new age in patient care.”
Michael Brown, Director, GE Research- HealthCare, ge.com

“I wanted to share what a great relationship we’ve started to build with MTEC, including several awards. The MTEC team and process for the award have significantly reduced administrative burden and paperwork, shortened timelines to award compared to other contract mechanisms, and provided knowledgeable staff. This is important because it allows our researchers to focus more on the science, and so we can provide military solutions to the field and to operational commands faster.”
Colonel Vik Bebarta, MD; Director, Center for COMBAT Research, University of Colorado Anschutz Medical Campus

Member Impact in Ukraine

Vascular injury is a leading cause of death and disability in military and civilian trauma. Humacyte’s Human Acellular Vessel (HAV), an off-the-shelf bioengineered blood vessel, is being used by Ukrainian surgeons to save lives and limbs by repairing vascular injuries resulting from shrapnel wounds, gunshots, and mine blast injuries. With $6.8M in funding from USAMRDC through MTEC, Humacyte was able to propel its manufacturing platform development forward to build the first commercial-scale tissue engineering system.

A significant challenge for medics in the field is finding a sterile environment in which to operate. The SurgiField System is a disposable, sterile, inflatable bubble developed to protect patients from contamination in austere environments. MTEC’s prototype acceleration award provided $250K to the SurgiBox team to collect user feedback from healthcare providers using SurgiField on the front lines in Ukraine.
Evolution of MTEC

100 Members

First Awards Issued

1st Sponsor: USAMRDC

MTEC incorporated, 501(c)(3) status awarded

2015

100 Members

MedTech Innovator Partnership

2016

New Sponsor: ONR

$100M in Awards

2017

Allergan Foundation Partnership

2018

First Completed Project

2019

New Sponsor: ONR

New Sponsors: WRAIR and ISR

Find for Sight Partnership

2020

New Sponsors: JOMIS and TATRC

$300M in Awards

New Sponsors: USARIEM and USUHS

ARCH Ventures Partnership

500 Members

$500M in Awards

2021

600 Members

Bright Focus Partnership

M-Corps Launched

2022

$700M in Awards

7 Commercial Products

$100M in Cost Share
MTEC Board of Directors

Walter “Skip” Auch, Jr., Principal, Auch Company LLC, investment banking

Mark D. Breyen, Medtronic, Inc. VP Research & Technology, Cardiac Implantables Technology Development Center

Gautam S. Ghatnekar, PhD, Chairman and CEO, Regranion, LLC

Kent Kester, MD, FACP, DIDSA, FASTMH, VP and Head, Translational Medicine for IAVI

Pierre Noel, MD, Mayo Clinic internal medicine physician and Director of Center for Military Medicine

MTEC Leadership

Bill Howell, President

Julia Martin, Chief Financial Officer

Dr. Lauren Palestrini, Chief Science Officer

Bill Evans, Treasurer

Jill Sorensen, Chief Development Officer

Andrew Omidvar, PhD, MBA, Philips Healthcare, Inc. VP of Enterprise and Government R&D for Healthcare

Ron Peropaticich, MD, Director of the Center for Military Medicine Research and Professor of Medicine at the University of Pittsburgh

Amy Salzhauer, PhD, MBA, Founder and Managing Partner of Good Growth Capital Ventures, LLC

Peter H. Soderberg, Managing Partner of Worthy Venture Resources LLC

Edward Steiner, JD, Partner in the Global Corporate Practice Group of Squire Patton Boggs LLP

Kathy Zolman, Chief of Consortium Operations

Dr. Susan Raymond, Director of Strategic Funding

Richard Satcher, Director of Commercialization

Rebecca Harmon, Chief Contracting & Compliance Officer

Scan to follow MTEC on social media
Tribute to CAPT (ret) Russ Keller

MTEC lost one of its founding partners who is remembered for his impact and proficiency in getting this endeavor off the ground and running. CAPT (ret) Russ Keller, a former Navy submariner, provided the initial impetus and continued drive to establish and improve the MTEC throughout his 6 years with the entity. Russ displayed infectious passion for the work. His wisdom and willingness to listen and analyze, moved the MTEC forward. As a military officer, he knew the mission needed to get done and worked hard in getting the infrastructure for success going early. He cared just as much for his staff as he did his family. The mission and people were his strong suits.

Russ was primarily responsible for the Advanced Technology International (ATI) portion supporting the MTEC’s contracting, financial management, internal project management, and information management. He realized that this OTA was going to be unique from others. Its dual use and high scientific risks brought forth opportunities to assist organizations that were not present or available in other OTAs. He grasped this concept and helped to make it a reality, for which we are all grateful.

With time, Russ and I built a strong bond. Together, we made decisions that affected the goals and trajectory of the MTEC. Russ is sorely missed by myself and the MTEC family to which he so dedicated himself. For his service to the nation, the MTEC mission, and the people with whom he worked, we salute him.

Always in our thoughts.

Bill Howell
2022 Highlights:

- 9 Solicitations, 62 awards, $154.4M awarded
- 2 New funding sponsors added to the MTEC
- MTEC Ventures established
- Initiated Advanced Commercialization Services

Join MTEC Membership
Visit mtec-sc.org